Advanced Non-Contrast Imaging for Cardiotoxicity Detection after Cancer

用于癌症后心脏毒性检测的先进非对比成像

• 批准号: 8524775
• 负责人: Holly Goodwin
• 金额: $ 29.97万
• 依托单位: ALBUS IMAGING LLC
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-23 至 2015-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8524775
• 关键词: Activities of Daily Living; Adjuvant; Adjuvant Chemotherapy; Age; Algorithms; Animal Model; Animals; Anthracyclines; Biological Markers; Breast Cancer Treatment; Cancer Patient; Cancer Survivor; Cardiac; Cardiomyopathies; Cardiotoxicity; Cardiovascular system; Clinical; Cohort Studies; Comorbidity; Control Groups; Data; Detection; Deterioration; Dose; Doxorubicin; Early treatment; Event; Exposure to; Fees; Fibrosis; Functional disorder; Future; Gadolinium; Goals; HIV; Health Sciences; Heart failure; Human; Hypertension; Image; Image Analysis; Injury; Intervention; Ionizing radiation; Left Ventricular Ejection Fraction; Legal patent; Link; Magnetic Resonance Imaging; Malignant Childhood Neoplasm; Malignant Neoplasms; Malignant neoplasm of prostate; Maps; Measures; Methods; Metric; Modeling; Morbidity - disease rate; Muscle function; Myocardial; Myocardial Infarction; Myocardium; Obesity; Patients; Performance; Phase; Physicians; Prevalence; Procedures; Process; Reporting; Research; Rest; Saline; Scanning; Schedule; Secure; Sensitivity and Specificity; Serum; Services; Site; Survivors; System; Techniques; Technology; Time; Translating; Troponin; Universities; Virus Diseases; Woman; Women' s Group; animal data; base; cancer therapy; cardiovascular imaging; cardiovascular injury; chemotherapy; diabetic; diabetic patient; forest; gadolinium oxide; improved; malignant breast neoplasm; mortality; novel; older women; outcome forecast; patient population; prevent; problem drinker; public health relevance; survivorship; tool; tumor; young woman

DESCRIPTION (provided by applicant): In this application, we propose to conduct research to advance our patented technologies that identify early evidence of cardiovascular (CV) injury upon the receipt of cardiotoxic chemotherapy for breast cancer patients. For these patients, the prevalence of cardiovascular events including heart failure (HF) is 18% - 22%, and represents the second leading cause of morbidity and mortality. We have identified a method to detect early evidence of myocellular injury which offers opportunities for early treatment so that these patients avoid permanent myocardial damage that causes HF. In this study, we propose to: 1) determine the utility of our analyses for identifying the myocellular injury associated with administration of doxorubicin. 2) determine the utility of our results to forecast future changes i left ventricular ejection fraction (LVEF) upon receipt of doxorubicin chemotherapy, and 3) determine the association between our results, LVEF and serum Troponin after receipt of doxorubicin chemotherapy. The results of this proposal will provide the data that is needed to develop this analytic model for the product that identifies the breast cancer patients who are the most susceptible to myocardial injury and LV dysfunction such that targeted interventions can be started to reduce the impact of these CV events. For these patients, our product will provide an integrated system of quantitative and longitudinal tracking of CV injury. In the future, this product can be scaled to include other patient populations in need of surveillance for cardiomyopathy such as, other cancer survivors, diabetics, the obese, and patients with viral infections.

描述(申请人提供)：在这项申请中，我们建议进行研究，以推进我们的专利技术，以识别乳腺癌患者接受心脏毒性化疗后心血管(CV)损伤的早期证据。对于这些患者，包括心力衰竭(HF)在内的心血管事件的患病率为18%-22%，是导致发病率和死亡率的第二大原因。我们已经确定了一种检测心肌细胞损伤的早期证据的方法，这种方法为早期治疗提供了机会，使这些患者避免导致心力衰竭的永久性心肌损伤。在这项研究中，我们建议：1)确定我们的分析在识别与阿霉素给药相关的心肌细胞损伤方面的有效性。2)确定我们的结果在预测接受阿霉素化疗后左室射血分数(LVEF)未来变化的有效性，以及3)确定我们的结果、LVEF与接受阿霉素化疗后血清肌钙蛋白之间的关系。这项建议的结果将提供为该产品开发这一分析模型所需的数据，该模型确定最容易受到心肌损伤和左心室功能障碍的乳腺癌患者，以便可以开始有针对性的干预，以减少这些心血管事件的影响。对于这些患者，我们的产品将提供一套完整的定量和纵向追踪脑血管损伤的系统。在未来，该产品可以扩大到包括其他需要监测心肌病的患者群体，如其他癌症幸存者、糖尿病患者、肥胖者和病毒感染患者。